Mark Sabag - 12 Feb 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, International Markets Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol: TEVA
Transactions as of: 12 Feb 2025
Net transactions value: -$2,886,565
Form type: 4
Filing time: 14 Feb 2025, 16:03:01 UTC
Previous filing: 30 Jan 2025
Next filing: 05 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Sale	$2,886,565	-177,626	-46%	$16.25	204,964	12 Feb 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.335, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Executive Vice President, International Markets Commercial